244 related articles for article (PubMed ID: 9770163)
1. Lipid formulations of amphotericin B: clinical efficacy and toxicities.
Wong-Beringer A; Jacobs RA; Guglielmo BJ
Clin Infect Dis; 1998 Sep; 27(3):603-18. PubMed ID: 9770163
[TBL] [Abstract][Full Text] [Related]
2. Overview of the lipid formulations of amphotericin B.
Dupont B
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
[TBL] [Abstract][Full Text] [Related]
3. The lipid formulations of amphotericin B.
Herbrecht R; Natarajan-Amé S; Nivoix Y; Letscher-Bru V
Expert Opin Pharmacother; 2003 Aug; 4(8):1277-87. PubMed ID: 12877636
[TBL] [Abstract][Full Text] [Related]
4. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
Clemons KV; Stevens DA
Antimicrob Agents Chemother; 2004 Mar; 48(3):1047-50. PubMed ID: 14982807
[TBL] [Abstract][Full Text] [Related]
6. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
7. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
8. Lipid-based formulations of amphotericin B.
Veerareddy PR; Vobalaboina V
Drugs Today (Barc); 2004 Feb; 40(2):133-45. PubMed ID: 15045035
[TBL] [Abstract][Full Text] [Related]
9. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
10. A comparative review of conventional and lipid formulations of amphotericin B.
Robinson RF; Nahata MC
J Clin Pharm Ther; 1999 Aug; 24(4):249-57. PubMed ID: 10475983
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B: time for a new "gold standard".
Ostrosky-Zeichner L; Marr KA; Rex JH; Cohen SH
Clin Infect Dis; 2003 Aug; 37(3):415-25. PubMed ID: 12884167
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B: clinical experience and perspectives.
Gibbs WJ; Drew RH; Perfect JR
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B colloidal dispersion.
Patel R
Expert Opin Pharmacother; 2000 Mar; 1(3):475-88. PubMed ID: 11249532
[TBL] [Abstract][Full Text] [Related]
15. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
16. Lipid formulations of amphotericin B.
Jones E; Goldman M
Cleve Clin J Med; 1998 Sep; 65(8):423-7. PubMed ID: 9769563
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.
Johansen HK; Gotzsche PC
Cochrane Database Syst Rev; 2000; (3):CD000969. PubMed ID: 10908480
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B lipid complex for the treatment of invasive fungal infections.
Linden PK
Expert Opin Pharmacother; 2003 Nov; 4(11):2099-110. PubMed ID: 14596663
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.
Steimbach LM; Tonin FS; Virtuoso S; Borba HH; Sanches AC; Wiens A; Fernandez-Llimós F; Pontarolo R
Mycoses; 2017 Mar; 60(3):146-154. PubMed ID: 27878878
[TBL] [Abstract][Full Text] [Related]
20. Liposomal formulations of amphotericin B: differences according to the scientific evidence.
Azanza JR; Sádada B; Reis J
Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
